TLDR:
- Bluejay Therapeutics secured $182 million in Series C financing to accelerate clinical development of BJT-778.
- The funding round was co-led by Frazier Life Sciences and a life science focused institutional investment firm.
Bluejay Therapeutics, a leader in novel therapeutics, recently announced the successful closure of a $182 million Series C financing round. The funding will be utilized to advance the clinical development of BJT-778, a potential treatment for chronic hepatitis D (HDV). The company also plans to progress other promising candidates in its pipeline for the treatment of chronic hepatitis B. BJT-778 has already received PRIME designation from EMA based on early results from the Phase 1/2 study in HDV.
The Series C financing was co-led by Frazier Life Sciences and a life science focused institutional investment firm, with contributions from new and existing investors such as RA Capital Management, T. Rowe Price, Wellington Management, and others. Following the funding, Daniel Estes from Frazier will join Bluejay’s Board of Directors. CEO Dr. Keting Chu expressed gratitude for the investors’ confidence in their mission and strategy, emphasizing the significance of addressing unmet medical needs globally.
